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Abstract
Background Despite the extensive use of bevacizumab in a range of oncology indications, the US FDA revoked its approval 
for breast cancers, and multiple negative trials in several solid malignancies have been reported, so the need for predictive 
biomarkers has increased. The development of predictive biomarkers for anti-angiogenic bevacizumab therapy has long 
been pursued but without success.
Introduction Heat shock protein (HSP)-27 expression has recently been identified as a predictive biomarker for bevacizumab 
in treating metastatic melanoma. This study aimed to evaluate the cost effectiveness of HSP27 biomarker testing before 
administration of bevacizumab.
Methods A partitioned survival analysis model with three mutually exclusive health states (progression-free survival, 
progressed disease, and death) was developed using a Norwegian health system perspective. The proportion of patients in 
each state was calculated using the area under the Kaplan–Meier curve for progression-free and overall survival derived 
from trials of bevacizumab and dacarbazine. Three strategies were compared: (1) test-treat with HSP27 biomarker and 
bevacizumab, (2) treat-all with dacarbazine without HSP27 testing, (3) treat-all with bevacizumab without HSP27 testing. 
Quality-adjusted life-years (QALYs) and costs were calculated for each strategy and discounted at 4%. A lifetime horizon 
was applied. Uncertainty analyses were performed. Expected value of perfect information (EVPI) was estimated to assess 
the potential value of further research to generate more evidence.
Results Although the test-treat strategy was cost effective compared with treat-all with dacarbazine, it was not cost effective 
compared with treat-all with bevacizumab without HSP27 testing. However, EVPI results showed very minimal or no value 
in conducting further research efforts to reduce uncertainties around current information.
Conclusion The results of this study suggested that testing for HSP27 expression before administering bevacizumab is 
not cost effective compared with treat-all with bevacizumab without testing. It indicates that HSP27 expression is not cost 
effective as a potential predictive biomarker for bevacizumab. This may not necessarily mean that HSP27 is a bad biomarker 
for bevacizumab, but it may mean that bevacizumab is much better than dacarbazine regardless of HSP27 expression, so 
patient stratification according to HSP27 status is meaningless. Or, indeed, it may imply that HSP27 is not sufficiently good 
at identifying the right patients for bevacizumab.
1 Introduction
Cutaneous malignant melanoma is common in fair-skinned 
populations in many countries [1-4]. Worldwide, 132,000 
melanoma skin cancers occur each year [5]. Incidence and 
mortality continue to rise across the world [4, 6-8]. Nor-
way has among the highest incidence of melanoma in the 
world [9]. In Norway, the 5-year relative survival is 90% for 
patients with localized melanoma but only 16% for those 
with distant melanoma [10].
The routinely available treatment options for metastatic 
melanoma were high-dose interleukin-2 and dacarbazine, 
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with a low response rate of around 10% [11-13]. Chemother-
apy has long been the main treatment option for metastatic 
tumours, even though it is marginally effective, with dac-
arbazine—the only US FDA-approved drug—the standard 
drug for most melanoma cases [9]. However, dacarbazine 
has shown low response rates with no life-extending effect 
[9]. Recently, new targeted drugs have been developed; in 
particular, the introduction of BRAF and MEK inhibitors 
has improved the progression-free survival (PFS) and overall 
survival (OS) of patients with advanced melanoma [14-20]. 
Immunotherapy has also improved the outlook for those 
with metastatic disease. Thus, biomarker-guided therapies 
have demonstrated considerable efficacy in the treatment of 
metastatic melanoma [21, 22]. Currently, the presence of 
a specific BRAF mutation is the biomarker recommended 
for routine clinical practice to administer the correspond-
ing targeted therapies (vemurafenib, dabrafenib, trametinib, 
cobimetinib) in advanced melanoma [21, 23-25]. In addi-
tion, immune checkpoint inhibition for metastatic mela-
noma has created significant optimism in recent years [15, 
26], but no predictive biomarkers have been validated for 
immunotherapy.
Given bevacizumab’s mechanism of action as a vascular 
endothelial growth factor (VEGF) inhibitor, certain patient 
populations might be less likely to benefit from the drug as 
indicated by measured VEGF levels. Thus, development of 
predictive biomarkers for bevacizumab has long been pur-
sued but without success. However, recently, a study identi-
fied heat shock protein (HSP)-27 as a potential predictive 
biomarker for bevacizumab in treating metastatic mela-
noma (ClinicalTrials.govt ID: NCT00139360) [27]. HSP27 
is associated with poor prognosis and treatment resistance 
in many cancers [28]. Schuster et al. [27] suggested that 
strong HSP27 tissue expression in melanoma metastasis 
can predict response to bevacizumab. Based on this recent 
study, our analysis aimed to assess the cost effectiveness of 
HSP27 testing before the administration of bevacizumab in 
patients with metastatic melanoma. Given the early stage 
of companion biomarker discovery, we also aim to inform 
decisions about investing in further research to generate 
more evidence. To the best of our knowledge, no economic 
evaluations of biomarker testing before the administration of 
bevacizumab for melanoma have been conducted.
2  Methods
2.1  Overview
A partitioned survival analysis model, similar to previous 
economic evaluations of treatments of advanced or meta-
static cancers, including the cost effectiveness of a BRAF 
inhibitor (dabrafenib) and bevacizumab [28, 29], was 
developed using Microsoft Excel. A hypothetical cohort of 
10,000 patients with metastatic melanoma was modelled. 
The model had three mutually exclusive health states: alive 
with no progression (PFS), alive with progression (pro-
gressed disease [PD]), or dead (Fig. 1). The proportion of 
patients in each health state over time was calculated using 
the Kaplan–Meier (KM) survival curves for PFS and OS. 
Partitioned survival analysis assumes that, at any discrete 
time point, the difference between the proportion of patients 
in OS and the proportion of patients in PFS determines the 
proportion of patients who are alive with PD.
A Norwegian health system perspective was employed, 
which considered direct costs in treating metastatic mela-
noma. The model has a monthly cycle and a lifetime hori-
zon to capture all consequences in health benefits and costs. 
Costs and health outcomes were discounted at 4% annually 
as recommended by the Norwegian Ministry of Finance 
and guidelines for health economic evaluation in the health 
sector [30]. The primary measure of cost effectiveness was 
the incremental cost per quality-adjusted life-year (QALY) 
gained.
2.2  Strategies compared
We compared and assessed three strategies in this study. 
The intervention strategy of interest was testing the HSP27 
biomarker status of patients before the administration of 
bevacizumab (hereafter, referred to as the test-treat strategy). 
This intervention strategy was compared against two com-
parator strategies: first, treating all patients with dacarbazine 
without HSP27 biomarker testing (hereafter, treat-all with 
Key Points for Decision Makers. 
Testing for heat shock protein (HSP)-27 expression 
before administering bevacizumab in patients with meta-
static melanoma was not cost effective when compared 
with treat-all with bevacizumab without testing. It may 
imply that HSP27 expression is not a good enough bio-
marker for bevacizumab in identifying patients likely to 
be responsive or unresponsive to the treatment.
Further research to identify a predictive biomarker 
for bevacizumab is yet to be achieved; however, the 
expected value of perfect information (EVPI) results 
showed either very low or no value would be obtained 
from research efforts to generate more evidence around 
the HSP27 biomarker for bevacizumab.
EVPI results clearly showed that investing in further 
study, such as a phase III trial, is not justified given the 
number of patients with metastatic melanoma in Norway.
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dacarbazine strategy), and, second, treating all patients with 
bevacizumab without HSP27 biomarker testing (hereafter, 
treat-all with bevacizumab strategy).
Under the test-treat strategy, patients who truly tested 
positive for HSP27 expression received bevacizumab (online 
supplementary material 1), and HSP27-negative patients 
received dacarbazine. However, for patients who falsely 
tested positive, the health effect of dacarbazine was assumed 
even though they were treated with bevacizumab. Also, we 
assumed that dacarbazine was efficacious in patients who 
truly or falsely tested negative because they were not treated 
with bevacizumab. Based on the findings of Schuster et al. 
[27], patients with HSP27 tissue expression with a staining 
index ≥4 were considered HSP27 biomarker positive, and 
those below index 4 were considered HSP27 negative.
2.3  Survival estimates for partitioned survival 
analysis modelling
The survival analysis for bevacizumab used PFS and OS 
KM data from the phase II study (35 patients) [31], which 
identified a potential predictive biomarker to guide admin-
istration of bevacizumab in treating patients with metastatic 
melanoma [27]. We obtained the individual patient dataset 
(IPD) from the clinical research group, which reported the 
clinical data beyond the published trial period. In this newly 
obtained IPD, only one patient was censored, and this IPD 
was used in simulating survival for the bevacizumab arms. 
Therefore, given that only one patient was censored by the 
end of the trial period of bevacizumab, use of the actual 
KM curves was preferred as it was not necessary to make 
assumptions regarding the parametric distribution of sur-
vival times. The OS and PFS survival curves for patients 
treated with bevacizumab are presented in supplementary 
material 1.
Dacarbazine survival was based on the PFS and OS KM 
curves from the dacarbazine arm of a phase III study (675 
patients) [32, 33]. This trial was selected based on patient 
characteristics such as age, Eastern Cooperative Oncology 
Group (ECOG) performance status, and sex, as they were 
broadly similar to those in the bevacizumab study (supple-
mentary material 2). No head-to-head trial and no pooled 
analysis (i.e. meta-analysis) provided a treatment effect for 
bevacizumab compared with dacarbazine for patients with 
metastatic melanoma. The KM OS and PFS survival curves 
were extracted using Digitizelt [34], and individual-level 
time-to-event data were reconstructed using an algorithm 
developed in R by Guyot et al. [35]. Parametric survival 
distributions were fitted to the individual patient data recon-
structed from the published KM curves using Stata (Stata-
Corp., 2015. Stata Statistical Software: Release 14. College 
Station, TX, USA). When fitting parametric survival distri-
butions to KM curves, the exponential, Weibull, log-logistic, 
log-normal, and gamma distributions were considered. The 
log-normal distribution was selected for OS and the gener-
alized gamma distribution was selected for PFS based on 
visual inspection, the Akaike information criterion (AIC) 
and the Bayesian information criterion (BIC). The pertinent 
parameters used in extrapolating survival are provided in 
supplementary material 3. The log-normal distribution pro-
vided the lowest AIC and BIC values for OS and the gener-
alised gamma distribution for PFS. AIC and BIC results are 
provided in supplementary material 4.
2.4  Costs
Costs were calculated from the perspective of the Norwegian 
healthcare system. Direct costs included drug costs (drug 
acquisition and administration), HSP27 biomarker testing 
costs and monitoring costs during and after drug admin-
istration [30, 31, 36-39]. Costs other than healthcare costs 
were not included. The costs for testing HSP27 biomarker 
status assumed the units of 200 µg/ml of HSP27 antibody 
and converted from $US to Norwegian krone (NOK) using 
the exchange rate of $US1 = NOK7.72, year 2019 values 
[36]. The drug costs depended on the acquisition price, the 
dosage, and the treatment duration. The estimated cost of 
dacarbazine assumed that 850 mg/m2 body surface was 
administered on day 1 and then once every 3 weeks by intra-
venous infusion. Dacarbazine could be administered for up 
to 24 months while in the PFS state and then no dacarbazine 
given afterwards. After the 24 months of treatment with dac-
arbazine, monitoring costs were included for patients con-
tinuing in PFS and PD states.
Patients received intravenous bevacizumab 10 mg/kg as 
an infusion on day 1 of a 2-week cycle until progression 
or for up to 12 cycles (24 weeks). Only monitoring costs 
were included for patients in PFS who had finished treatment 
PFS; progression-free survival, PD; progressed disease. 
PFS PD
Dead
Fig. 1  The diagram of health states included in the model
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after 6 months. Monitoring costs were considered in PFS 
and PD states. Treatment was assumed to cease on progres-
sion. Cost calculations were made with respect to a monthly 
cycle length of 30.42 days. An average body weight of 80 kg 
was assumed. The dosages used in this model follow the 
information in the summary of product characteristics or 
trial protocol. Details of the costs are shown in Table 1.
2.5  Health outcome (quality‑adjusted life‑years)
The primary health outcome of interest in this analysis was 
QALYs gained. However, utility data on HSP27 testing and 
bevacizumab in metastatic melanoma were not available, 
so we used utility values from another study, which at least 
collected utility data on dacarbazine. The health state utility 
values were based on data collected in the BREAK-3 trial of 
dabrafenib versus dacarbazine using the EuroQoL-5 Dimen-
sions, 3 Levels instrument [40]. The health state utility of 
patients receiving dacarbazine was 0.750. Patients treated 
with bevacizumab were assumed to have the same health 
state utility as those receiving dabrafenib (0.767). The health 
state utility of all patients following progression was 0.677.
2.6  Cost‑effectiveness threshold
Whether or not the test-treat strategy is cost effective 
depends on how much a payer is willing to pay for addi-
tional health outcomes gained (QALYs or life-years [LYs]). 
When the intervention strategy is both cheaper and more 
effective than comparator strategies, it is a dominant strategy 
and clearly recommended as the optimal strategy to imple-
ment. However, if the intervention strategy is more effec-
tive and more expensive than comparator strategies, deci-
sions should be made according to the cost-effectiveness 
threshold (CET) set by healthcare payers. Norway does not 
have a specific CET, but the Ministry of Health have argued 
that NOK275,000 per additional QALY gained is the best 
estimate of the opportunity cost of healthcare in Norway 
[41]. While it is suggested that a higher CET per QALY 
should be accepted for more serious conditions [41], and 
NOK500,000 per QALY has been used for some disease 
conditions, NOK275,000 per QALY was used in this study 
in the absence of an explicit definition of what constitutes a 
serious condition.
2.7  Receiver operating characteristic analysis
Receiver operating characteristic (ROC) analysis was con-
ducted using the clinical trial data [27] to estimate the opti-
mal threshold of true-positive fraction and false-positive 
fraction of HSP27 biomarker testing. ROC analysis is a 
simple but useful tool to evaluate the accuracy of a diagnos-
tic test [42]. The ROC curve shows the trade-off between 
sensitivity and specificity; any increase in sensitivity will 
lead to a decrease in specificity. The closer the curve follows 
the left-hand border of the ROC curve, the more accurate 
the test. Meanwhile, the closer the curve comes to the 45° 
diagonal of the ROC curve, the less accurate the test. ROC 
curve analysis was used to test the performance of a test 
in identifying eligible patients for the treatment of inter-
est. In Fig. 2, the true-positive rate (sensitivity) is plotted 
against the false-positive rate (1-specificity) for a series of 
cut-off points of a parameter. It predicted the optimal cut-off 
threshold of HSP27 biomarker testing performance at the 
sensitivity of 81.8%. Following this ROC analysis, a sensi-
tivity of 81.8% and specificity of 41.7% were incorporated 
in the cost-effectiveness model. Given the low specificity, we 
also considered a higher index, but when an HSP27 staining 
index >4 was applied (which is staining index 6 or 9 in this 
case), it was worse than the random selection (45° diagonal 
Table 1  Cost inputs used in the 
model
HSP27 heat shock protein 27, NOK Norwegian krone, PSA probabilistic sensitivity analysis, SA sensitivity 
analysis






 Drug acquisition cost per cycle (NOK) 1259 881 1637 Gamma [38]
 Administration cost per treatment (NOK) 1312 918 1706 Gamma [38]
 Number of doses per cycle 1.33 – – – [37]
Bevacizumab
 Drug cost per mg (NOK) 415.49 291 540 Gamma [39]
 Number of doses per cycle 2 – – – [31]
 Average body weight (kg) 80 56 104 Normal Assumption
Monitoring cost per cycle (NOK) 2858 2001 3715 Gamma [38]
HSP27 testing kit (NOK) 1583 1108 2057 Gamma [36]
Discount rate 4% – – – [30]
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of the ROC space). For example, under HSP27 index 6, both 
sensitivity and specificity improved to over 90% but were 
located below the 45° diagonal of the ROC curve (Fig. 2). 
The estimated cut-off thresholds according to different levels 
of the HSP27 staining indices are reported in supplementary 
material 5. Thus, based on the ROC analysis results (Fig. 2), 
the best cut-off threshold for determining HSP27 biomarker 
positivity or negativity is at staining index 4.
2.8  Uncertainty analysis
2.8.1  Sensitivity analysis: handling parameter uncertainty
We conducted deterministic sensitivity analysis (DSA) to 
identify key drivers in the model while holding all other 
variables at their baseline values. We also performed proba-
bilistic sensitivity analysis (PSA) to assess the uncertainty 
around the base-case incremental cost-effectiveness ratio 
(ICER) by varying all relevant parameters simultaneously 
[43]. When available, we used the bounds of 95% confidence 
intervals (CIs) as high and low estimates in the sensitivity 
analysis. When the bounds of 95% CIs were unavailable, we 
used a range of ± 30%. Survival estimates were based on a 
beta distribution. Distributions of cost inputs used for PSA 
are detailed in Table 1. Monte Carlo simulation was used 
to assess the effect of simultaneous variation of all relevant 
parameters [44]. Additionally, we performed scenario analy-
ses for sensitivity and specificity of the HSP27 expression 
testing to examine their impact on the cost-effectiveness 
results.
2.8.2  Expected value of perfect information (EVPI): 
handling decision‑making uncertainty with current 
evidence
Healthcare decisions made based on existing information 
incur the costs of uncertainty. If an incorrect decision is 
made based on existing information, opportunity costs will 
be incurred in terms of healthcare resources and health ben-
efits. The expected costs of uncertainty can be interpreted as 
EVPI because perfect information can remove the possibility 
of making incorrect decisions [45]. The opportunity costs of 
making incorrect decisions can be estimated using the value-
of-information techniques. The EVPI estimates the upper 
bound of the value of conducting further research.
3  Results
3.1  Base‑case results
The base-case ICER per QALY for the test-treat strategy 
(bevacizumab plus HSP27 testing) compared with treat-
all patients with dacarbazine without HSP27 testing was 
NOK21,069, being cost effective. However, the test-treat 
strategy was not cost effective when compared with treat-all 
with bevacizumab without HSP27 testing (Table 2) because 
it cost less and produced fewer QALYs (Table 2). To be 
cost effective in this situation, the ICER needs to be above 
the CET, otherwise, the cost saving is not compensating 
adequately for the loss of benefit. In other words, we should 
be able to save costs per QALY at a rate above the CET, oth-
erwise, it is not worth giving up the QALYs and we would 
rather keep them. The base-case ICER results were clearly 
lower than the Norwegian CET (NOK275,000).
3.2  Sensitivity analysis results
3.2.1  Tornado diagram
The DSA results are presented in a tornado diagram (sup-
plementary material 6). The key drivers in the model were 
the bevacizumab costs and the proportion of HSP27-positive 
patients. However, they did not ultimately change the cost-
effectiveness decision.
3.2.2  Probabilistic sensitivity analysis
PSA was performed to assess the effect of parameter vari-
ation across all relevant parameters on the base-case ICER 
when all parameters simultaneously varied. We ran 1000 
simulations with QALYs gained as effectiveness measures. 
The total costs and QALYs gained for individuals tested for 
HSP27 and treated with bevacizumab were NOK94,740 and 
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Fig. 2  Receiver operating characteristics (ROC) curve
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7.80 QALYs, whereas those for patients simply treated with 
dacarbazine were NOK1450 and 2.91 QALYs, respectively 
(Table 3). Therefore, the ICER per QALY was NOK19,079.
However, the test-treat strategy was not cost effective 
when compared with the treat-all with bevacizumab strat-
egy. It saved costs but produced fewer QALYs as observed in 
the base-case results. Likewise, the cost savings per QALY 
need to be above the CET in order for the intervention strat-
egy to be cost effective. However, the ICER per QALY was 
NOK13,796, far below the Norwegian CET.
The scatterplot of the incremental costs and incremental 
QALYs from these simulations are presented in Figs. 3 and 
4. All the iterations were contained in the north-east quad-
rant of Fig. 3, which means that the test-treat strategy of bev-
acizumab and HSP27 biomarker testing is costlier and more 
effective than the strategy of treating all patients with dacar-
bazine without HSP27 testing. However, when the test-treat 
strategy was compared with the treat-all with bevacizumab 
strategy, a majority of the 1000 simulations were located in 
the south-west quadrant of the scatterplot, suggesting that 
the intervention strategy is less costly but also less effective 
(Fig. 4). The PSA results confirmed that, although the test-
treat strategy was cost effective compared with treat-all with 
dacarbazine, it was not cost effective compared with treat-
all with bevacizumab without HSP27 testing, and base-case 
results were robust to changes in all variables.
3.2.3  Scenario analysis on the sensitivity and specificity 
of HSP27 expression testing
Scenario analysis was performed to examine the impact 
of the sensitivity and specificity of HSP27 testing on the 
cost-effectiveness results. It did not change the results in 
the different scenarios of the sensitivity and specificity of 
HSP27 testing under the different staining index of HSP27 
expression. The cost-effectiveness results according to dif-
ferent combination scenarios of sensitivity and specificity of 
HSP27 expression testing are provided in Table 4.
3.3  EVPI analysis results
EVPI estimated the expected value of a decision made with 
current information against perfect information (Eq. 1).
Equation 1. Expected value of perfect information
where π refers to unknown parameters, NB the net benefit, 
t the treatment, and NB(t, π) the net benefit of treatment if 
parameters take the value π.
A willingness-to-pay threshold of NOK275,000 was 
assumed in the EVPI analysis. The EVPI was estimated at 
NOK5910 for the test-treat strategy versus treat-all with bev-
acizumab, whereas the EVPI was estimated at zero value for 
the comparison of the test-treat strategy and treat-all with 
dacarbazine (Table 5). The EVPI for the test-treat strategy 
against the treat-all with dacarbazine strategy implies that 
further research to reduce the uncertainties around current 
information would not be warranted. Likewise, the EVPI 
of NOK5910 for the test-treat strategy against the treat-all 
with bevacizumab implies further research might not be 
worthwhile either, given the small number of new cases 
of metastatic melanoma in Norway (annual average of 173 
cases [10]). The upper bound of the population EVPI of the 
comparative analysis between the test-treat and the treat-all 
bevacizumab strategy was only NOK1,022,430 per annum. 
EVPI = Ep[maxtNB(t, p)] −maxtEp[NB(t, p)],
Table 2  Base-case cost-
effectiveness results
Bmab bevacizumab, DTIC dacarbazine, HSP27 heat shock protein 27, ICER incremental cost-effectiveness 




Costs (NOK) Incremental 
costs (NOK)
ICER (per QALY)
Treat-all strategy with DTIC 2.92 – 1482 –
Test-treat strategy (HSP27 + Bmab) 8.25 5.33 113,857 112,374 21,069
Treat-all strategy with Bmab 10.36 2.11 146,583 32,727 15,515
Table 3  Scenario analysis 
results
Bmab bevacizumab, DTIC dacarbazine, HSP27 heat shock protein 27, ICER incremental cost-effectiveness 




Costs (NOK) Incremental 
costs (NOK)
ICER (per QALY)
Treat-all strategy with DTIC 2.91 – 1450 –
Test-treat strategy (HSP27 + Bmab) 7.80 4.89 94,740 93,290 19,079
Treat-all strategy with Bmab 9.87 2.07 123,339 28,598 13,796
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In other words, to justify further investment in research 
efforts of data collection such as conducting a phase III trial 
for HSP27 testing and bevacizumab, the research costs need 
to be lower than this upper bound, which is very unlikely for 
Norway. EVPI results are provided in Table 5. The EVPI 
graph depicted in Fig. 5 shows the change of EVPI depend-
ing on different thresholds. The spike is when we have maxi-
mum uncertainty where CET equals the ICER.
Fig. 3  Probabilistic sensitivity 
analysis (PSA) scatterplot for 
test-treat strategy compared 
with treat-all with dacarbazine
Test-treat strategy’s probability of being cost-effecve against treat-all with dacarbazine strategy at 
the Norwegian CET: 100%. 
CET; cost-effecveness threshold, NOK; Norwegian Krone, PSA; probability sensivity analysis, QALYs; quality-




















Fig. 4  Probabilistic sensitivity 
analysis (PSA) scatterplot for 
test-treat strategy compared 
with treat-all with bevacizumab
Test-treat strategy’s probability of not being cost-effecve against treat-all with bevacizumab at the 
Norwegian CET: 74.9%.
CET; cost-effecveness threshold, NOK; Norwegian Krone, PSA; probabilisc sensivity analysis, QALYs; 
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4  Discussion
The cost effectiveness of administering bevacizumab to 
those testing positive for HSP27 was compared with two 
alternative strategies (treating all patients with bevacizumab 
without HSP27 testing and treating all patients with dacar-
bazine without HSP27 testing) using a partitioned survival 
model. From the Norwegian health system perspective, a 
strategy of HSP27 biomarker testing was not cost effective. 
Treating all patients with bevacizumab is the best of the 
three strategies. This is the first study analysing the cost 
effectiveness of HSP27 biomarker testing before the admin-
istration of bevacizumab. No cost-effectiveness analyses 
of potential biomarkers (newly discovered yet unregistered 
for routine clinical use) in metastatic melanoma have been 
conducted.
Previous studies have assessed the cost effectiveness of 
BRAF and MEK inhibitors in metastatic melanoma. Delea 
et al. [29] evaluated the cost effectiveness of BRAF inhibi-
tors but did not assess the impact of BRAF testing separately. 
Tarhini et al. [46] assessed the sequence of different targeted 
therapy options in melanoma but did not consider biomarker 
status. Curl et al. [47] also estimated the cost effectiveness 
of treatments for patients with BRAF-mutated metastatic 
melanoma. Likewise, Bohensky et al. [48] conducted a cost 
effectiveness analysis for the treatment of BRAF wild-type 
advanced melanoma in Australia, but all patients entering 
the model had BRAF wild-type melanoma. However, none 
of these studies analysed the cost effectiveness of biomarker 
testing before the provision of corresponding targeted thera-
pies. However, Oh et al. [49] analysed the cost effective-
ness of targeted therapy depending on the biomarker status 
(programmed death ligand-1 [PD-L1]-positive and -negative 
patients) and found that PD-L1 biomarker status contributed 
the most uncertainty to their model.
This study has several limitations. First, the survival 
data for dacarbazine were derived from one clinical study 
not through meta-analysis. We found no meta-analysis of 
the effect of dacarbazine, so we chose a study based on the 
patient characteristics in a clinical trial among other studies 
considered for dacarbazine monotherapy for patients with 
metastatic melanoma [50, 51]. Although the survival data 
for HSP27 testing and bevacizumab were derived from a 
small single-arm study, these were the only clinical data 
available on HSP27 expression and bevacizumab for patients 
with metastatic melanoma. Second, bevacizumab does not 
have marketing authorization for metastatic melanoma. 
However, the objective of this study was to determine the 
value of HSP27 testing in terms of cost effectiveness and 
EVPI. Third, given the early stage of development of the 
HSP27 biomarker for bevacizumab, we had to make some 
assumptions with regard to HSP27 testing. Fourth, it is a 
naïve indirect comparison and we did not match patients 
Table 4  Scenario analysis 
results





Sensitivity (%) Specificity (%) ICER per QALY (NOK)
Test-treat strategy against 
treat-all with dacarbazine
Test-treat strategy against 
treat-all with bevacizumab
8 36.4 12.5 36,737 11,453
6 72.7 50.0 22,634 13,989
4 81.8 58.3 21,069 15,515
3 90.9 95.8 19,818 18,234
2 100 100 18,794 24,450
Table 5  EVPI results
EVPI expected value of perfect information, Max maximum, MNB mean net benefit, NOK Norwegian 
krone




Max mean (NOK) Mean max (NOK) EVPI (NOK)
2,474,879 910,986 2,474,879 2,474,879 0




Max mean Mean max EVPI (NOK)
2,464,076 3,097,583 3,097,583 3,103,493 5910
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between dacarbazine and bevacizumab. This may lead to 
some potential bias in the results. For example, patients in 
the dacarbazine trial were younger than those in the bevaci-
zumab trial; however, ECOG performance status was better 
for patients in the bevacizumab trial than for those in the 
dacarbazine trial. Also, the prognosis of female patients with 
metastatic melanoma is known to be better than that of male 
patients. However, both trials showed the same proportion of 
male and female participants. Fifth, utility values were not 
available for patients with metastatic melanoma treated with 
bevacizumab. However, utility values for patients treated 
with dacarbazine were available, and the model applied 
utility values for a targeted therapy for patients treated with 
bevacizumab.
5  Conclusion
The cost-effectiveness results showed that testing HSP27 
biomarker status before the administration of bevacizumab 
was not cost effective. This finding may imply that this 
HSP27 biomarker is not good enough at identifying the right 
patients for treatment, as shown in the results of the ROC 
curve analysis or that bevacizumab is much better than dac-
arbazine in terms of health outcomes regardless of whether 
eligible patients are identified. The EVPI suggests that no 
further research is required to generate more evidence for 
assessing the test-treat strategy against treat-all with dac-
arbazine; however, it suggests some health gains to reduce 
the uncertainties around the comparative analysis of the test-
treat and treat-all with bevacizumab strategies. Depending 
on the budget required to conduct further studies such as 
clinical trials, the decisions regarding additional research 
efforts can be reasonably determined by Norwegian stake-
holders by considering the expected gain in health and the 
upper bound of the monetary value of perfect information 
as suggested by EVPI.
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